726249
O-(2-Azidoethyl)nonadecaethylene glycol
≥95% (oligomer purity)
Synonym(s):
Azido-PEG (n=19)
About This Item
Recommended Products
![2-[2-(2-Azidoethoxy)ethoxy]ethanol solution ~0.5 M in tert-butyl methyl ether](/deepweb/assets/sigmaaldrich/product/structures/374/007/eea7ca74-41e4-4aac-af71-c93c37ec0a5a/640/eea7ca74-41e4-4aac-af71-c93c37ec0a5a.png)
Quality Level
Assay
≥95% (oligomer purity)
form
solid
storage temp.
2-8°C
SMILES string
OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCN=[N+]=[N-]
InChI
1S/C40H81N3O20/c41-43-42-1-3-45-5-7-47-9-11-49-13-15-51-17-19-53-21-23-55-25-27-57-29-31-59-33-35-61-37-39-63-40-38-62-36-34-60-32-30-58-28-26-56-24-22-54-20-18-52-16-14-50-12-10-48-8-6-46-4-2-44/h44H,1-40H2
InChI key
FRLHZVCZJNPUMK-UHFFFAOYSA-N
Related Categories
Packaging
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Articles
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service